Tumor TARGET Prostate Cancer

NAActive, not recruitingINTERVENTIONAL
Enrollment

85

Participants

Timeline

Start Date

October 31, 2012

Primary Completion Date

May 31, 2025

Study Completion Date

May 31, 2025

Conditions
Prostate Cancer
Interventions
RADIATION

Volumetric Modulated Arc Therapy (VMAT) and High-Dose Rate (HDR) Radiotherapy

"Patients in this group will receive one of 2 treatment arms of their choice:~* Arm 1: VMAT delivery with integrated VMAT boost (IB-VMAT) GTV: 95Gy in 38fractions~* Arm 2: HDR-boost followed by VMAT GTV: 10Gy HDR + 76Gy in 38 fractions VMAT"

OTHER

No Active Treatment - completed Prior Radiation

Already had prior radiation treatment. MRI-guided prostate biopsy at 3 years and PSA per standard practice

Trial Locations (1)

M5G 2M9

University Health Network, The Princess Margaret, Toronto

All Listed Sponsors
collaborator

Princess Margaret Hospital, Canada

OTHER

lead

University Health Network, Toronto

OTHER

NCT01802242 - Tumor TARGET Prostate Cancer | Biotech Hunter | Biotech Hunter